|
|
|
|
|
Orphenadrine
drug data and news
Orphenadrine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Orphenadrine | ||
| Brand Names/Synonyms | Antiflex; BS-5930; Banflex; Biorphen; Brocadisipal; Brocasipal; Disipal; Flexoject; Mephenamine; Mio-Rel; Myolin; Myotrol; Norflex; O-Methyldiphenhydramine; Orfro; Orphenadine; Orphenadrin; Orphenadrine; Orphenadrine Citrate; Orphenate; Orphenedrine; WS 2434 | ||
| Indication | Indicated for the treatment of Parkinson's disease. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia. | ||
| Mechanism Of Action | Orphenadrine binds to both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect. | ||
| Orphenadrine News (When available) |
| ||
| Dosage Forms | TABLET (EXTENDED-RELEASE) | ||
| Drug_Category | Muscle Relaxants; Antiparkinson Agents; Antidyskinetics; Skeletal Muscle Relaxants; ATC:M03BC01; ATC:N04AB02 | ||
| Absorption | Orphenadrine is almost completely absorbed in the gastrointestinal tract. | ||
| Interactions |
Interactions for Orphenadrine: No information provided. | ||
| Toxicity | Oral, mouse LD50 = 100mg/kg. Oral, rat LD50 = 255 mg/kg | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N,N-dimethyl-2-[(2-methylphenyl)-phenyl-methoxy]-ethanamine | ||
| Chemical Formula | C18H23NO | ||
| Molecular Weight | 269.381 g/mol | ||
| Smiles String | CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C | ||
| Melting Point | 156-157 °C | ||
| Water Solubility | Sparingly soluble in water | ||
| State | Solid | ||
| LogP/Hphobicity | 4.034 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Biotransformation occurs mainly in the liver. Pharmacologically active metabolites are N-demethyl orphenadrine and N,N-didemethyl orphenadrine. | ||
| Half Life | 13-20 hours | ||
| Protein Binding [%] | 95% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Orphenadrine.html http://www.rxlist.com/cgi/generic/orphen.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00097 | ||
| CAS Registry Number | 83-98-7 | ||
| KEGG Compound ID | C07935 | ||
| PubChem ID | SID:10137 | ||
| PharmGKB ID | PA450715 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2243559 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |